Molecular structure of Cefoxitin, CAS Number: 35607-66-0
Cefoxitin (CAS 35607-66-0)
See product citations (5)
Alternate Names:
(6R,7S)-3-[[(Aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic Acid
CAS Number:
35607-66-0
Molecular Weight:
427.45
Molecular Formula:
C16H17N3O7S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cefoxitin is a beta-lactam antibiotic that has been the subject of numerous studies focusing on its biochemical and environmental interactions. In research pertaining to bacteriology, cefoxitin is examined for its efficacy in inhibiting bacterial cell wall synthesis due to its resistance to certain beta-lactamases. This attribute makes it a subject of interest in the study of antibiotic resistance mechanisms and the evolution of resistant bacterial strains. Environmental scientists are also interested in the degradation of cefoxitin in various ecosystems to understand how antibiotic compounds disperse and break down in nature, as well as the implications for antibiotic resistance. Additionally, its interactions with bacterial enzymes are analyzed in biochemical research to develop novel inhibitors that can combat resistant bacteria.
Cefoxitin (CAS 35607-66-0) References
- Cefoxitin is both an inhibitor of class A beta-lactamase of Xanthomonas campestris pv. campestris str. 17 and an inducer of its gene. | Tsuey-Ching, Y., et al. 2012. Res Microbiol. 163: 550-6. PMID: 22910283
- Phenotypic detection of mecC-MRSA: cefoxitin is more reliable than oxacillin. | Skov, R., et al. 2014. J Antimicrob Chemother. 69: 133-5. PMID: 24038776
- In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. | Lavollay, M., et al. 2014. Clin Microbiol Infect. 20: O297-300. PMID: 24112243
- Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. | Kernéis, S., et al. 2015. Infect Dis (Lond). 47: 789-95. PMID: 26136072
- Antimicrobial Hyaluronic Acid-Cefoxitin Sodium Thin Films Produced by Electrospraying. | Ahire, JJ. and Dicks, LM. 2016. Curr Microbiol. 73: 236-41. PMID: 27146506
- Cefoxitin Prophylaxis During Pediatric Cardiac Surgery: Retrospective Exploration of Postoperative Trough Levels. | Ricci, Z., et al. 2019. Pediatr Infect Dis J. 38: 484-489. PMID: 30169486
- Reassessing the dosing of cefoxitin prophylaxis during major abdominal surgery: insights from microdialysis and population pharmacokinetic modelling. | Boisson, M., et al. 2019. J Antimicrob Chemother. 74: 1975-1983. PMID: 31220258
- Antibiotic prophylaxis with high-dose cefoxitin in bariatric surgery: an observational prospective single center study. | Belveyre, T., et al. 2019. Antimicrob Agents Chemother. 63: PMID: 31591127
- Cefoxitin-Serum Creatinine Interference in a Patient With Nontuberculous Mycobacteria Ventriculomeningitis. | Wang, D., et al. 2021. J Pharm Pract. 34: 658-661. PMID: 32351174
- How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection? | Pilmis, B., et al. 2021. Eur J Clin Microbiol Infect Dis. 40: 1393-1397. PMID: 33502648
- Cefoxitin treatment of MRSA leads to a shift in the IL-12/IL-23 production pattern in dendritic cells by a mechanism involving changes in the MAPK signaling. | Eld, HMS., et al. 2021. Mol Immunol. 134: 1-12. PMID: 33676343
- Staphylococcus pseudintermedius's PBP4 Is Directly Associated with the Dissociated Oxacillin and Cefoxitin Phenotype. | Gagetti, P., et al. 2021. Antibiotics (Basel). 10: PMID: 34827237
- Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. | Loeuille, G., et al. 2022. Antibiotics (Basel). 11: PMID: 35453211
- Is Cefoxitin a Carbapenem Sparing Agent in the Management of Urinary Tract Infections Caused by ESBL Producing Enterobacterales? | El Nekidy, WS., et al. 2022. Hosp Pharm. 57: 568-574. PMID: 35898247
- Gold Nanoparticle-Based Resuscitation of Cefoxitin against Clinical Pathogens: A Nano-Antibiotic Strategy to Overcome Resistance. | Alafnan, A., et al. 2022. Nanomaterials (Basel). 12: PMID: 36296833
- Detection of Oxacillin/Cefoxitin Resistance in Staphylococcus aureus Present in Recurrent Tonsillitis. | Messias, ACMC., et al. 2023. Microorganisms. 11: PMID: 36985189
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cefoxitin, 100 mg | sc-504743 | 100 mg | $316.00 | |||
Cefoxitin, 1 g | sc-504743A | 1 g | $556.00 |